A cluster of clinical news in biosimilars has been announced over the last few days, with pooled data sets against reference products, an expected launch of a novel study, and a cost efficiency analysis. Beyond that, an expert in the field has shared his perspective on the challenges and ongoing need for education on biosimilars.
- Lee S, Lee H, Kim E. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in rheumatoid arthritis and non-Hodgkin’s lymphoma: a systematic review and meta-analysis [published online August 22, 2019]. BioDrugs. doi: 10.1007/s40259-019-00376-z.
- McBride A, Krendyukov A, Mathieson N, et al. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma [published online August 21, 2019]. J Med Econ. doi: 10.1080/13696998.2019.1658591.
... to read the full story